RT Journal Article
SR Electronic
T1 Discovery of Metastasis-Associated Biomarkers in Ovarian Cancer Using SELDI-TOF: An in Vitro and Clinical Study
JF Clinical Oncology and Cancer Research
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 317
OP 321
DO 10.1007/s11805-009-0317-2
VO 6
IS 5
A1 Zhiguo Zheng
A1 Yun Gao
A1 Linhui Gu
A1 Hanzhou Mou
A1 Chihong Zhu
A1 Jianqing Zhu
A1 Shenhua Xu
YR 2009
UL http://www.cancerbiomed.org/content/6/5/317.abstract
AB OBJECTIVE To identify metastasis-related biomarkers in human ovarian cancer cell lines and in serum.METHODS We isolated total protein from cell lysis solutions and cultured supernatants from 2 human ovarian cancer cell lines and used SELDI-TOF-MS to detect the differential expression of the proteins in the 2 cell lines. The proteomic spectra were generated using weak cation exchange chips. The biomarkers were validated by analyzing serum proteins or peptides in ovarian cancer patients, relapsed ovarian cancer patients, patients with benign ovarian tumors, and healthy people.RESULTS Four proteins in the culture supernatant from HO-8910PM cells were up-regulated, relative to the culture supernatant of HO-8910 cells. One protein (3,144 Da m/z value) was up-regulated in both the cell lysis solution and in the culture supernatant of HO-8910PM cells. In addition, expression of the 3,144 Da m/z protein differed significantly between serum from the 26 ovarian cancer patients, from the 22 relapsed ovarian patients and from the 37 healthy women (P < 0.01). However, there was no difference between patients with benign ovarian tumors and healthy people (P > 0.5).CONCLUSION Ovarian cancer cell lines with high or low metastatic potential have distinct protein profiles. Protein 3,144 Da m/z could be a useful biomarker for diagnosing ovarian cancer metastasis.